A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

ADMA Biologics' growth potential with Asceniv makes it a compelling Buy. Click here to find out why ADMA stock is a Strong ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day’s high of $1.11 ...